A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial.

What Was Tested

The paper reports a study of Magnesium and Riboflavin in the context of migraine, published as a randomized controlled trial.

Previous studies of magnesium and feverfew for migraine prophylaxis have found conflicting results, and there has been only a single placebo-controlled trial of riboflavin.

Who Took Part

The study group was 120 patients.

PubMed tags the participants as both men and women.

The protocol allowed for 120 patients to be randomized, with a preplanned interim analysis of the data after 48 patients had completed the trial.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Magnesium study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Magnesium, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Magnesium group a baseline to be compared against.

The study included a 1-month run-in phase and 3-month trial.

What Was Measured

PubMed files the paper under topics including Drug Combinations, Magnesium, Migraine Disorders, Phytotherapy, Plant Preparations, Riboflavin and Tanacetum parthenium.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Magnesium and Riboflavin in 120 patients in people with migraine.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Headache), a journal based in United States.

More context: the related Vitamin D, K2, Magnesium and Zinc library page, Migraine research.